Arterial blood pressure fluctuates with a pattern that follows a circadian rhythm, with a peak in the early morning hours and a trough during nighttime. Nocturnal dipping of arterial blood pressure is part of this normal circadian pattern, and its absence, which is called non-dipping is associated with more severe end-organ damage and increased risk of cardiovascular events, especially in hypertensive patients. Although pathologic mechanisms are still unclear, it has been suggested that non-dippers show impairment in the autonomic system functions that include abnormal parasympathetic and sympathetic activities. Several studies have examined the role of the autonomic nervous system in the non-dipping phenomenon. In this paper, we aimed to review the studies evaluating the relationship between circadian arterial blood pressure pattern and indices of cardiac autonomic functions.
1 November 2008 in Integrated Blood Pressure Control
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing
1 January 2013 in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
Objectives. This study aimed to demonstrate that irbesartan is successful in reducing diastolic blood pressure (BP) even following a missed dose after 6–8-weeks’ treatment as measured by 24-hour ambulatory BP monitoring (ABPM). Methods. Eighty-eight patients (64 females, mean age: 53.4 ± 10.6 years) with primary hypertension were included in this national, single-center, single-arm, open-label, prospective clinical study. Irbesartan (150 or 300 mg/day) was administered for 8 weeks. All patients were asked to cease treatment for 1 day during weeks 6–8. Changes in diastolic and mean 24-hour BP on the day of cessation and diastolic BP values during visits were efficacy parameters. Adverse events were also recorded. Results. Systolic, diastolic, and mean BP values measured via ABPM before and on the day of a missed dose did not differ significantly. Irbesartan effectively controlled BP of the patients. BP normalization rates were 54% for 150 mg/day irbesartan only and 77% for both doses (150 or 300 mg/day) of irbesartan. None of the patients experienced serious adverse events throughout the study period. Conclusions. Irbesartan is successful and safe in the control of BP levels even following a missed dose at the end of a 6–8-week treatment period.